Diagnos Inc.

Diagnos Inc.

April 09, 2015 10:51 ET

DIAGNOS Announces Retina Screening Project with Clinique Chifa Hydra in Algeria

BROSSARD, QUEBEC--(Marketwired - April 9, 2015) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today a retina screening project with Clinique Chifa Hydra in Algeria.

Clinique Chifa Hydra, owned by Dr. A. Larbaoui, is one of the largest private clinics in Algeria. The clinic prides itself on its use of sophisticated equipment and has an endocrinology department entirely dedicated to patients with diabetes, making the clinic a perfect fit for DIAGNOS' tele-ophthalmology services. This preliminary contract is valid for one year with possibility for renewal and expansion.

"Following the opening of an Algerian subsidiary, SARL DIAGNOS MEDICAL, and the opening of DIAGNOS' own clinical retinopathy screening office, DIAGNOS is continuing its expansion in Algeria. Starting this month, we will be providing screening services, software, and hardware in Clinique Chifra Hydra, contributing to our overall presence in the Middle East and North Africa region," said André Larente, DIAGNOS' President.


Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About DIAGNOS Healthcare

DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.

Contact Information

  • Andre Larente
    DIAGNOS Inc.
    (450) 678-8882 ext 224